Clearmind Medicine Engages Bar-Ilan University to Evaluate Anti-Addictive Properties of Clearmind's Proprietary MEAI Compound
Toronto, Ontario--(Newsfile Corp. - November 18, 2021) - Clearmind Medicine Inc. (CSE: CMND) (FSE: CWY0) (OTC Pink: CMNDF) ("Clearmind" or the "Company"), a psychedelic medicine biotech company focused on the discovery and development of novel psychedelic-derived therapeutics to solve widespread and undertreated health problems, today announces it has signed an R&D agreement with Professor Gal Yadid from the Gonda Multidisciplinary Brain Research Center located at Bar Ilan University (Ramat...
2021-11-18 8:00 AM EST
Clearmind Medicine Announces Sponsorship of Wonderland Psychedelic Conference in Miami
Toronto, Ontario--(Newsfile Corp. - November 8, 2021) - Clearmind Medicine Inc. (CSE: CMND) (FSE: CWY0), ("Clearmind" or the "Company"), a psychedelic medicine biotech company focused on the discovery and development of novel psychedelic-derived therapeutics to solve widespread and undertreated health problems, announced today its participation at the Wonderland Miami Conference organized by Microdose.Wonderland Miami Conference is the largest in-person conference in the psychedelic medicine...
2021-11-08 11:45 AM EST
Clearmind Medicine To Fund Second R&D Partnership With Hebrew University's Technology Transfer Company
Toronto, Ontario--(Newsfile Corp. - September 27, 2021) - Clearmind Medicine Inc. (CSE: CMND) ("Clearmind" or the "Company"), a psychedelic medicine biotech company focused on the discovery and development of novel psychedelic-derived therapeutics to solve widespread and undertreated health problems, is pleased to announce it has entered an agreement to fund a second research and development project with Yissum Research Development Company ("Yissum"), the technology transfer company of The...
2021-09-27 7:00 AM EDT
Clearmind Medicine Holds Annual and Special Shareholders Meeting
Toronto, Ontario--(Newsfile Corp. - September 2, 2021) - Clearmind Medicine Inc. (CSE: CMND) ("Clearmind" or the "Company"), a psychedelic medicine biotech company focused on the discovery and development of novel psychedelic-derived therapeutics to solve widespread and undertreated health problems, today announces that all resolutions were duly passed by shareholders at the Company's Annual and Special Meeting held on September 1, 2021."I am pleased to welcome Oz and Oded to our Board of...
2021-09-02 1:28 PM EDT
Clearmind Medicine Commences Trading on the Frankfurt Stock Exchange
Toronto, Ontario--(Newsfile Corp. - August 18, 2021) - Clearmind Medicine Inc. (CSE: CMND) ("Clearmind" or the "Company"), a psychedelic medicine biotech company focused on the discovery and development of novel psychedelic-derived therapeutics to solve widespread and undertreated health problems, is pleased to announce the listing of its common shares for trading on the Frankfurt Stock Exchange ("FSE") under the symbol CWY0.The FSE is the world's third largest trading exchange, ranking only...
2021-08-18 7:00 AM EDT
Clearmind Announces Changes To Senior Management As It Accelerates Development Of Its IP Portfolio
Toronto, Ontario--(Newsfile Corp. - July 14, 2021) - Clearmind Medicine Inc. (CSE: CMND) ("Clearmind" or the "Company"), a psychedelic medicine biotech company focused on the discovery and development of novel psychedelic-derived therapeutics to solve widespread and undertreated health problems, is pleased to announce changes to its executive management team in conjunction with an accelerated effort to execute the strategic shift to psychedelic drug development as defined in its May 25th...
2021-07-14 7:00 AM EDT
Clearmind Medicine Inc. Retains Edge Communications Group for Investor Relations and Announces Granting of Stock Options
Toronto, Ontario--(Newsfile Corp. - July 2, 2021) - Clearmind Medicine Inc. (CSE: CMND) ("Clearmind" or the "Company"), a psychedelic medicine biotech company focused on the discovery and development of novel psychedelic-derived therapeutics to solve widespread and under-served health problems, today announced that it has retained Edge Growth Holdings Corporation ("Edge Communications Group" or "Edge") for strategic investor relations and capital markets communications services (the...
2021-07-02 8:00 AM EDT
Clearmind Medicine Inc. Announces Closing of Previously Announced Private Placements for Aggregate Gross Proceeds of CAD$6.225 Million at CAD $0.75 per Unit
Toronto, Ontario--(Newsfile Corp. - June 30, 2021) - Clearmind Medicine Inc. (CSE: CMND) ("Clearmind" or the "Company"), a psychedelic medicine biotech company focused on the discovery and development of novel psychedelic-derived therapeutics to solve widespread and under-served health problems, today announced that (further to its press releases of May 27, 2021, and June 20, 2021) that it has closed its previously announced private placement (the "Offering") for an aggregate amount of...
2021-06-30 7:30 AM EDT
Clearmind Medicine Inc. Announces Increase to Previously Announced Non-Brokered Private Placement
Toronto, Ontario--(Newsfile Corp. - June 20, 2021) - Clearmind Medicine Inc. (CSE: CMND) ("Clearmind" or the "Company"), a psychedelic medicine biotech company focused on the discovery and development of novel psychedelic-derived therapeutics to solve widespread and under-served health problems, today announced that, further to its press release of May 27, 2021, it intends to increase its previously announced private placement from gross proceeds of $6,000,000 to a maximum of up to $6,225,000...
2021-06-20 9:18 PM EDT
Clearmind Medicine Inc. Announces Non-Brokered Private Placement and Granting of Stock Options
Toronto, Ontario--(Newsfile Corp. - May 27, 2021) - Clearmind Medicine Inc. (CSE: CMND) ("Clearmind" or the "Company"), a psychedelic medicine biotech company focused on the discovery and development of novel psychedelic-derived therapeutics to solve widespread and under-served health problems, today announced that it intends to raise a minimum of $3,750,000 and a maximum of up to $6,000,000 (the "Gross Proceeds") by way of a non-brokered private placement (the "Private Placement"). The...
2021-05-27 2:43 AM EDT
Cyntar Ventures Inc. Completes Change of Business Listing as it Shifts Focus to Psychoactive Pharmaceuticals for Underserved Health Issues Under the Name Clearmind Medicine Inc.
Toronto, Ontario--(Newsfile Corp. - May 25, 2021) - Clearmind Medicine Inc. (CSE: CMND) ("Clearmind" or the "Company"), today announced it has completed all requirements of the Canadian Securities Exchange (the "CSE" or the "Exchange") for a Change of Business ("COB") listing. Formerly Cyntar Ventures Inc, the Company is shifting from a mineral resource exploration operation to the research and development of innovative psychedelic therapeutics.The Company first announced the COB in September...
2021-05-25 2:07 AM EDT